Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.84) by 2.38 percent. This is a 8.89 percent increase over losses of $(0.90) per share from the same period last year. The company reported quarterly sales of $3.740 million which missed the analyst consensus estimate of $10.360 million by 63.90 percent. This is a 20.90 percent decrease over sales of $4.728 million the same period last year.